Clinical Trials Logo

Cardiogenic Shock clinical trials

View clinical trials related to Cardiogenic Shock.

Filter by:

NCT ID: NCT05700617 Not yet recruiting - Heart Failure Clinical Trials

Cardiac Power Output in Cardiogenic Shock Patients

Start date: July 2024
Phase: Early Phase 1
Study type: Interventional

The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.

NCT ID: NCT05586282 Not yet recruiting - Septic Shock Clinical Trials

Role of Candidate Proteins in Capillary Leakage During Acute Circulatory Failure

Start date: November 2022
Phase:
Study type: Observational

- Testing the association between circulating candidate proteins and the level of vascular leakage for three distinct forms of circulatory failure: cardiogenic shock, septic shock, and post-resuscitation syndrome. - Describing immuno-inflammatory profiles associated with massive vascular leakage during those three forms of circulatory failure in humans

NCT ID: NCT05339854 Not yet recruiting - Clinical trials for Myocardial Infarction

Evaluation of eCPR Survivors

Start date: June 1, 2023
Phase:
Study type: Observational

A cardiac arrest event has severe impact on the patient´s health-related quality of life. Survival of cardiac arrest does not innately translate to favorable quality of life. In particular, highly invasive resuscitation strategies, including extracorporeal cardio-pulmonary resuscitation (ECPR) due to therapy-refractory cardiac arrest, may have impact on long-term outcomes. Therefore, apart from acute medical treatment and physical rehabilitation, long-term effects on cardio-pulmonary, physical and neuro-psychiatric functions after cardiac arrest survival have to be evaluated and optimized. We plan to investigate a bundle of cardio-pulmonary, physical and neuro-psychiatric functions in patients who survived a therapy-refratory cardiac arrest with ECPR.

NCT ID: NCT05331001 Not yet recruiting - Clinical trials for Myocardial Infarction

Quality of Care in Centers Providing Extracorporeal Membrane Oxygenation

Start date: June 1, 2022
Phase:
Study type: Observational [Patient Registry]

Cardiac arrest centers are specialized in treating critically ill patients with severe cardiovascular diseases, such as cardiac arrest, cardiogenic shock or acute myocardial infarction. Diagnostic and therapeutic measures, such as the use of devices for extracorporeal life support, require highly specialized training and skills. Apart from extensive medical expertise, physicians and nurses may be exposed to exceptional levels of occupational stressors. Therefore, excellent medical, psychological and inter-personal training of the medical staff is essential to improve patient outcomes. Assessment of quality of care is important to provide continuous improvement in patient care and team performance. To the best of our knowledge, there is no study which examined the quality of care in cardiac arrest centers across key dimensions of quality of care. Therefore, we aim to assess a bundle of key dimensions, that is psychological strain (P), resource utilization (R), interaction (I) between doctoral and nursing staff, costs of care (C) and education (E) programs for staff (PRICE scheme). A cross-sectional study will be conducted with doctors and nurses, using a digital quesitonnaire that will cover the five dimensions of the PRICE scheme.

NCT ID: NCT05106491 Not yet recruiting - Cardiogenic Shock Clinical Trials

Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients

PulseSE
Start date: September 2024
Phase: N/A
Study type: Interventional

The study aims to investigate the safety and efficacy of the Synchronized Cardiac Support treatment wit the icor kit and the Xenios console with modified sensor box ECG and Software Version 3.2.4

NCT ID: NCT05064202 Not yet recruiting - Cardiogenic Shock Clinical Trials

Unloading in Heart Failure Cardiogenic Shock

UNLOAD HF-CS
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this research study is to evaluate whether timely and aggressive temporary Mechanical Circulatory Support (tMCS) through the Impella 5.5® in patients with acute decompensated heart failure complicated by cardiogenic shock (ADHF-CS) has the potential to reduce the HF-CS related clinical events compared to the current standard of care.

NCT ID: NCT04989777 Not yet recruiting - Cardiogenic Shock Clinical Trials

IABP In AMI Patients With SCAI-B Study

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Acute myocardial infarction (AMI) is the most common cause of cardiogenic shock (CS), and CS is the most common cause of death in patients with AMI. Percutaneous mechanical circulation is one of the most important techniques in the treatment of AMICS. Intra-aortic balloon pump (IABP) is the most commonly used mechanical circulatory assist device in clinic. However, the existing clinical evidence shows that IABP can not improve the clinical outcome of patients with AMICS. As for impella and extracorporeal membrane oxygenation (ECMO) system, there was still no difference in overall mortality compared with IABP in AMICS. Until now, IABP-shock II study is the largest randomized controlled study so far. However, this study has limitations. In a recent retrospective study, the project team investigated the use of IABP and the outcomes of more than 300 AMI cases in three provincial capitals of Northeast China in 2016. It was found that the 28 day survival rate of patients in the early use of IABP group was significantly higher than that in the late use group. The investigators speculate that IABP may significantly improve the clinical outcomes of patients with AMICS if it can be used in the earlier stage of CS (stage B). This multicenter, prospective, randomized controlled study will involve 512 participants in about 15 centers. Patients diagnosed with AMI (including STEMI and NSTEMI) complicated with shock stage B (SCAI definition criteria) received early revascularization (PCI or CABG) and standardized drug treatment according to the current guidelines before meeting the study inclusion criteria. After reviewing the inclusion criteria, participants were randomized to two groups (IABP group and control group) in a ratio of 1:1. The investigators speculated that IABP could significantly improve the clinical outcomes of patients with AMICS if it could be used in the earlier stage of CS (stage B). At present, there is no clinical study on the use of IABP in AMICS (stage B). It is worth carrying out the corresponding clinical research, in order to study the real role of IABP in patients with AMICS and explore the treatment strategy of AMICS in line with China's national conditions.

NCT ID: NCT04850248 Not yet recruiting - Cardiogenic Shock Clinical Trials

Scoring Model for Predicting Outcome in Patients With Cardiogenic Shock

Start date: July 1, 2021
Phase:
Study type: Observational

This study aims to develop a predictive model for the outcomes of patients with cardiogenic shock

NCT ID: NCT04689451 Not yet recruiting - Pulmonary Embolism Clinical Trials

Feasibility and Safety of Total Percutaneous Closure of Femoral Arterial Access Sites in the Veno-arterial ECMO Patients

Start date: February 1, 2021
Phase:
Study type: Observational

The most frequent access site for veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is the common femoral artery (CFA), using either an open or percutaneous technique. Currently, percutaneous closure devices for femoral arterial access sites are approved for use only when a 10-F or smaller sheath has been used. However, the availability of the Perclose ProGlide (Abbott Laboratories, Chicago, IL) device has now made it possible to perform percutaneous vessel closure after using larger sheaths.The preclose technique using Perclose ProGlide, has been widely used in endovascular procedures. In a prospective randomized study, complication rates at the access site were similar in patients who underwent total percutaneous access (including percutaneous arteriotomy closure) than in those who underwent surgical cutdown and subsequent surgical closure. Total percutaneous closure of femoral arterial access sites increases patient comfort and decreases the rate of wound infections and lymphatic fistulas.[6,7] Furthermore, patients are mobilized and discharged earlier following the use of closure devices than with compression alone. Despite the above observations, no data have been published regarding percutaneous closure of femoral artery access sites in patients who have undergone VA-ECMO. In this study, we evaluated the safety and feasibility of a percutaneous closure technique using Perclose ProGlide to close the CFA access site after VA-ECMO.

NCT ID: NCT04478188 Not yet recruiting - Cardiogenic Shock Clinical Trials

Pressure Volume Loop

Start date: August 2020
Phase:
Study type: Observational

The investigators are doing this study and medical record review to measure simultaneous pressure and volume of the heart called pressure volumes loops before and after ventricular assist device placement for cardiogenic shock ( a severe form of heart failure). Standard of care measurements will be the sole measure of clinical determination. The investigators are measuring these PV loops to help determine which patients heart have recovered and can have the ventricular assist device removed. The investigators are also using the PV loop to indicate/correlate with certain outcomes to predict the need for LVAD patients to require additional support in the form of a right ventricular assist device. The medical record review will be performed pre-operatively, intra-operatively, and post-operatively until the day of discharge.